MammaPrint+BluePrint欣扶你乳癌肿瘤基因双效检测
分子医学权威Agendia公司 │ 一家尖端的肿瘤基因检测及精准医疗的国际企业

Agendia通过分析人类全部基因组，实现无偏差基因选择，研发出各种乳癌检测产品，包括

     

Agendia公司是位於荷兰的一家尖端的肿瘤基因检测及精准医疗的国际企业，致力於研发并销售基因检测相关的诊断产品，协助医师制订复杂的治疗方针；除此以外，Agendia公司更联合各大型制药企业、领先的癌症医学中心和医疗相关的学术机构共同研发更多关於肿瘤领域的诊断检测。


MammaPrint乳癌复发风险检测 + BluePrint分子亚型检测

上述这两种基因检测产品都是基於微阵列技术而研发出，而Agendia还有其它更多的基因检测产品尚在研发测试中。
Agendia位於荷兰阿姆斯特丹(Amsterdam)和美国加州(California)两间实验室，不只荣获美国FDA认证，还获得ISO 13485与美国病理学会(The College of AmericanPathologists，CAP)，以及其他方性政府机关的认证，值得您的信赖！
Ref: Eur. J. Neurosci., 28, 2365-2370,2008 https://www.agendia.com/licenses-and-accreditations/

About Agendia

From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions. Through every step, we continue to stay focused on providing the innovation and dedication that helps patients live better lives.

Here are a few of our company highlights:

2003—Agendia was founded as a spin-off of the Netherlands Cancer Institute in Amsterdam

2004—We launched our flagship breast cancer risk of recurrence test, MammaPrint, in Europe

2007—MammaPrint became the first IVDMIA* to gain 510(k) clearance from the FDA, and has since received six additional FDA clearances

2007—We launched MammaPrint in the US

2010—We introduced our second breast cancer test, BluePrint, a molecular subtyping test

2016—The landmark MINDACT trial was published, demonstrating the clinical utility of MammaPrint with the highest possible level of evidence (level 1A)

2017—MammaPrint was recommended in prestigious clinical practice guidelines including ASCO, the only test of its kind recommended for both lymph node-negative and lymph node-positive patients

2017—Publication of the STO-3 trial demonstrated that patients with a MammaPrint Late recurrence (20-year) Low Risk result had excellent breast cancer-specific survival, 20 years after diagnosis with little or no hormone therapy

2018—The MammaPrint and BluePrint Kit attained the CE mark, allowing leading cancer centers across Europe to run these tests in their own labs using their existing next-generation sequencing (NGS) technology†

2018—MammaPrint and BluePrint were launched to patients and physicians in China